Dr. John Mayer Goldberg M.D. Net Worth

Dr. John Mayer Goldberg M.D. biography

Dr. John Mayer Goldberg M.D. is the Sr. VP of Clinical Devel. at Oncorus.

How old is Dr D?

Dr D is 47, he's been the Sr. VP of Clinical Devel. of Oncorus since . There are 9 older and no younger executives at Oncorus. The oldest executive at Oncorus, Inc. is Dr. Mitchell H. Finer Ph.D., 62, who is the Co-Founder & Non-Exec. Chairman.

What's Dr D's mailing address?

John's mailing address filed with the SEC is C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE, MA, 02139.

Insiders trading at Oncorus

Over the last 4 years, insiders at Oncorus have traded over 1,276,271$ worth of Oncorus stock and bought 2,354,001 units worth 35,555,648$ . The most active insiders traders include Ansbert Gadicke、Luke Evnin、James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of 15,538$. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth 87,421$.

What does Oncorus do?

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Oncorus executives and stock owners

Oncorus executives and other stock owners filed with the SEC include:

• Stephen W. Harbin,
  COO & Chief of Staff
• Dr. Theodore T. Ashburn M.D., Ph.D.,
  Pres, CEO & Director
• Dr. Theodore T. Ashburn,
  Pres, CEO & Director
• Dr. Christophe Queva Ph.D.,
  Chief Scientific Officer & Sr. VP of Research
• Stephen Harbin,
  COO & Chief of Staff
• Dr. Mitchell H. Finer Ph.D.,
  Co-Founder & Non-Exec. Chairman
• Dr. Mitchell H. Finer,
  Co-Founder & Exec. Chairman
• Chris German,
  Controller
• Brian J. Shea,
  Director of Legal Counsel & Corp. Sec.
• Richard J. Wanstall M.B.A.,
  CFO, Chief Accounting Officer & Treasurer
• Dr. John Mayer Goldberg M.D.,
  Sr. VP of Clinical Devel.
• John McCabe M.B.A.,
  CFO, Treasurer & Sec.
• Scott A Canute,
  Director
• Rick Wanstall,
  CFO and Treasurer
• Theodore Ashburn,
  President and CEO
• Christophe Queva,
  CSO and SVP, Research
• James E Deerfield Mgmt Hif,...,
  
• Luke Evnin,
  Director
• Oncology Impact Fund L.P.On...,
  
• Ansbert Gadicke,
  10% owner
• Mitchell H. Finer,
  Director
• Bio Ventures 2014, L.P.Fole...,
  
• Spencer Nam,
  Director
• Sun States Fund, L.P.Mpm As...,
  
• Stephen Harbin,
  COO and Chief of Staff
• John P. Mc Cabe,
  CFO and Treasurer
• Mary Kay Fenton,
  Director
• Eric Rubin,
  Director
• Barbara Yanni,
  Director
• John Mayer Goldberg,
  Chief Medical Officer
• James E Deerfield Mgmt Hif,...,
  
• Douglas Fambrough,
  Director